CD226 and Miyoshi myopathy: Proteosome inhibitors, such as bortezomib, also enhance anti-MM NK cell killing by downregulating HLA-I (110), upregulating NKG2D and DNAM-1 ligands (106), and increasing tumor cell susceptibility to NK cell activity via upregulation of the TRAIL and FasL apoptotic pathways (111).